Pharmaceutical

EyePoint Pharmaceuticals gets grant for treatment of ocular conditions with multi-specific compounds

Discover the groundbreaking patent by EyePoint Pharmaceuticals Inc for treating ocular conditions with multi-specific compounds targeting phosphatase and receptor tyrosine kinase agonists. Revolutionize eye care with Tie2 activation and VEGF inhibition.

May 1, 2024 - 00:00
Discover the groundbreaking patent by EyePoint Pharmaceuticals Inc for treating ocular conditions with multi-specific compounds targeting phosphatase and receptor tyrosine kinase agonists. Revolutionize eye care with Tie2 activation and VEGF inhibition.
Read the original article

Tags:

Previous Article

Inovio Pharmaceuticals gets grant for electroporation device with adjustable nee...

Next Article

FDA approves rare illness medication Xolremdi by X4

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

FDA accepts BeiGene’s sNDA for follicular lymphoma therapy

FDA accepts BeiGene’s sNDA for follicular lymphoma therapy

Jul 13, 2023

Arrivo targets major depressive disorder in females after early efficacy data

Arrivo targets major depressive disorder in females aft...

Oct 30, 2024

STAT+: USDA to push food producers to substantiate claims that animals are raised without antibiotics

STAT+: USDA to push food producers to substantiate clai...

Jun 16, 2023